Home > Boards > US Listed > Biotechs >


Add PETX Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/18/2018 11:19:19 AM - Followers: 35 - Board type: Free - Posts Today: 0

Welcome to Aratana Therapeutics 

Aratana Therapeutics is a biopharmaceutical company positioned to deliver innovative prescription medicines that address significant medical needs for cats and dogs (companion animals). 

The company licenses proprietary, patent-protected compounds from human pharmaceutical and biotechnology companies.  Aratana’s team of veterinary drug development experts then advance these compounds through clinical studies designed expressly for demonstrating safety and efficacy in the target specie(s).  Aratana believes the development and commercialization of these therapeutics  will permit veterinarians and companion animal owners to manage pets' medical needs safely and effectively. 

Pets are our passion because pets are family.

About Aratana Therapeutics 

Company Overview 

Companion animals are living longer and therefore are at higher risk of developing an increasing number of medical conditions such as allergies, arthritis, diabetes, cancer and obesity; however, few treatment options exist for these conditions today.   

Aratana is positioned to address this need for better pet care by bringing human science to animal health and providing veterinarians with innovative new medicines that have been designed specifically for treating pets.   

Aratana’s unique “pet-centric” approach differs fundamentally from the current standard, which often involves adjusting the dose of marketed human drugs, which are only presumed to be safe and effective in animals based on human data and veterinary experience. There is significant demand amongst veterinarians and pet owners for higher quality medicines that have been specifically studied and approved by regulatory authorities for each species. Aratana’s team of drug development and commercial experts are dedicated to developing innovative treatments in accordance with regulatory standards to meet these needs. 

Mission and Strategy 

Aratana's mission is to find, develop and commercialize safe and effective therapeutics to enhance the quality of life and strengthen the bond between people and their pets. Our strategy is to become the leading provider of therapeutics developed and approved specifically for the treatment of unmet medical needs in pets. We intend to help shape and define the pet therapeutics market by identifying, acquiring and developing high-value commercial products for companion animals in a cost effective and efficient manner. 


Aratana is currently developing several compounds for the large and growing pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence, and a recently licensed non-opioid local anesthetic for treating post-operative pain. These compounds, which are being developed individually for both cats and dogs, are supported by substantial safety and efficacy data and, if approved by regulatory authorities, could become best- or first-in-class products in the animal health industry. 

The company is actively identifying additional programs to in-license from human health companies in order to expand its development pipeline of animal medicines

Corporate Headquarters
1901 Olathe Blvd 
Kansas City, Kansas 66103
(913) 951-2132

Other Locations
200 Clarendon Street; 54th Floor 
Boston, Massachusetts 02116
(617) 425-9226


Business Development Contacts
Julia A. Stephanus 
Chief Commercial Officer
(913) 951-2139

Erick J. Lucera, CPA, CFA 
Vice President, Corporate Development
(913) 951-2136


Investor and Media Contacts
Tiberend Strategic Advisors, Inc. 
35 West 35th Street; 11th Floor
New York, New York 10001
(212) 827-0020

Investors - Joshua Drumm, PhD 
(212) 375-2665

Media - Andrew Mielach 
(212) 375-2694


Transfer Agent and Registrar
American Stock Transfer & Trust Company, LLC. 
(800) 937-5449

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PETX News: GALLIPRANT® (grapiprant tablets) Named Best Companion Animal Product for 2017 01/18/2018 08:00:00 AM
PETX News: Statement of Changes in Beneficial Ownership (4) 01/12/2018 05:38:20 PM
PETX News: Current Report Filing (8-k) 01/11/2018 08:26:59 AM
PETX News: Elanco, Aratana Announce Marketing Authorization of GALLIPRANT® (grapiprant tablets) in Europe 01/11/2018 08:20:00 AM
PETX News: Statement of Changes in Beneficial Ownership (4) 12/21/2017 06:10:51 PM
#345   unfortunately none of this is reflected in PETX terry hallinan 01/18/18 11:19:19 AM
#344   Good post, unfortunately none of this is reflected Traderbx 01/18/18 10:41:31 AM
#343   GALLIPRANT® (grapiprant tablets) Named Best Companion Animal Pr terry hallinan 01/18/18 10:13:55 AM
#342   Agreed, thanks and I like your last statement: "an Traderbx 01/11/18 11:40:28 AM
#341   post says news in India... what does this mean? terry hallinan 01/11/18 11:20:11 AM
#340   Terry I followed your link, the post says Traderbx 01/11/18 10:40:28 AM
#339   The news of European marketing may open another terry hallinan 01/11/18 10:28:15 AM
#338   Nice! Thanks for the post Traderbx 01/11/18 08:47:50 AM
#337   Elanco, Aratana Announce Marketing Authorization of GALLIPRANT® (grapiprant runcaly 01/11/18 08:46:13 AM
#336   I hear ya Terry... atleast we moving in Traderbx 12/24/17 04:11:26 PM
#335   As required by USDA to progress from conditional terry hallinan 12/24/17 11:42:49 AM
#334   PETX wins conditional approval for treating canine osteosarcoma: https://finan Traderbx 12/20/17 10:34:39 AM
#333   so are you saying that the ADXS vaccine terry hallinan 12/18/17 09:22:01 AM
#332   so are you saying that the ADXS vaccine biotech2 12/17/17 07:58:41 AM
#331   I'm more curious about AT-014 terry hallinan 12/15/17 07:44:34 PM
#329   I'm more curious about AT-014, and PETX has Traderbx 12/15/17 07:01:33 PM
#328   Aratana Therapeutics Announces Study Results for AT-016 terry hallinan 12/15/17 05:12:58 PM
#327   Indeed. It's starting to creep (well plummet) awfully SamSalters 12/04/17 04:10:44 PM
#326   This dog is out of breath !! PETX sandman44 12/04/17 03:59:19 PM
#325   Form 4 Broadfin runcaly 12/02/17 02:36:26 PM
#324   Glad I shorted this a few weeks ago. terry hallinan 12/01/17 08:50:49 PM
#323   Glad I shorted this a few weeks ago. SamSalters 12/01/17 01:15:24 PM
#322   LQQKS like things back fired on CLOWN MANAGEMENT sandman44 11/30/17 03:39:40 PM
#321   Sounds like management is a little short when sandman44 11/29/17 10:29:11 AM
#320   Wow that was pretty sneaky of management terry hallinan 11/29/17 09:39:13 AM
#319   Wow that was pretty sneaky of management sandman44 11/29/17 09:09:42 AM
#318   Good vibrations are back :) Rhew123 11/29/17 07:30:06 AM
#317 :-) Best, Terry terry hallinan 11/29/17 07:26:43 AM
#316   Dang. They misbehaved, market backhanded them, and they Rhew123 11/29/17 07:24:32 AM
#315   Wow no more offering TheKobra 11/29/17 05:44:53 AM
#314   Previcox was the drug we first got from terry hallinan 11/28/17 10:57:43 PM
#313   (Galliprant's) sitting stagnant on shelves at the price terry hallinan 11/28/17 05:05:38 PM
#312   Yeah $35 million doesn't go far in the SamSalters 11/28/17 03:23:05 PM
#311   They will HAVE to do this capital raise biotech_researcher 11/28/17 03:20:57 PM
#310   I shorted Aratana after it ran up a SamSalters 11/28/17 03:18:11 PM
#309   Oh, I completely agree on future prospects and Rhew123 11/28/17 02:51:18 PM
#308   Man, they sure buzzkilled our good vibrations didn’t they!? terry hallinan 11/28/17 02:38:43 PM
#307   Man, they sure buzzkilled our good vibrations didn’t they!? Rhew123 11/28/17 02:13:57 PM
#306   I think we'll get some news today ... runcaly 11/20/17 04:47:58 AM
#305   Galliprant works just like other NSAIDS it just terry hallinan 11/11/17 02:45:46 PM
#304   "Terry, I think you are missing his point, terry hallinan 11/10/17 08:18:34 PM
#303   Thanks for your thoughts as well. I agree SamSalters 11/10/17 05:39:28 PM
#302   Thanks Sam. I understand. Most of my Galliprant BlueRayn 11/10/17 05:32:44 PM
#301   BlueRyan, I know I guess I didn't word SamSalters 11/10/17 05:26:49 PM
#300   Galliprant has nothing to do with appetite. Entyce BlueRayn 11/10/17 05:15:17 PM
#299   Terry, I think you are missing his point, biotech_researcher 11/10/17 04:41:32 PM
#298   I think Aratana is definitely making the right terry hallinan 11/10/17 02:57:48 PM
#297   Sam, I agree 100% on what you stated. biotech_researcher 11/10/17 02:28:18 PM
#296   Terry, I think Aratana is definitely making the SamSalters 11/10/17 01:16:40 PM
#295   A Dog of a Stock Suddenly Jumps Up terry hallinan 11/05/17 11:32:54 AM